Background: LDL-cholesterol (LDL-C) concentrations are the primary basis for treatment guidelines established for hyperlipidemic patients. LDL-C concentrations are commonly monitored by means of the Friedewald formula, which provides a relative estimation of LDL-C concentration when the triglyceride concentration is <2000 mg/L and there are no abnormal lipids. The Friedewald formula has several limitations and may not meet the current total error requirement of <12% in LDL-C measurements. Methods: We evaluated the analytical and clinical performance of two direct methods (Roche and Wako) by analyzing 313 fresh serum samples obtained from dyslipidemic patients in a lipid clinic and comparing them with modified ␤-quantification. Results: Both homogeneous assays displayed excellent precision (CV <2%). The Roche method showed a mean total error of 7.72%, and the Wako method showed a mean total error of 4.46% over a wide range of LDL-C concentrations. The Roche method correlated highly with the modified ␤-quantification assay (r ‫؍‬ 0.929; y ‫؍‬ 1.052x ؊ 168 mg/L; n ‫؍‬ 166) and showed a bias of ؊4.5% as a result of the assigned standard value. The Wako method also correlated highly with ␤-quantification (r ‫؍‬ 0.966; y ‫؍‬ 0.9125x ؉ 104.8 mg/L; n ‫؍‬ 145) without significant bias. The Roche method correctly classified 97% of patients with triglycerides <2000 mg/L, 75% of patients with type IIb hyperlipemia (HPL), and 84% of patients with type IV HPL based on the cutpoints of 1300 and 1600 mg/L, compared with 98%, 78.4%, and
89%, respectively, for the Wako method. In dysbetalipoproteinemic patients, both methods have a 30% mean positive bias compared with ␤-quantification. Conclusions: Both direct methods can be a useful alternative when ultracentrifugation is not available for the diagnosis and control of lipid-lowering medication for patients with mixed HPL, but not for patients with type III hyperlipidemia.
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Numerous epidemiological and clinical studies have reported an independent relationship between increases in LDL-cholesterol (LDL-C) 4 concentrations and risk for the development of coronary heart disease (1, 2 ) . In dietetic and pharmacological intervention studies, it has been stated that lowering of LDL-C concentrations reduces morbidity and cardiovascular mortality (3, 4 ) . Because LDL-C plays a causal role in the development of atherosclerosis, the National Cholesterol Education Program (NCEP) Adult Treatment Panel (5 ) and other scientific societies have identified LDL-C concentrations as the primary criterion for diagnosis and treatment of patients with hyperlipemia (HPL).
Although the measurement LDL-C is important, an easy, reliable, and suitable methodology for LDL-C has never existed in routine laboratories. ␤-Quantification currently is considered the reference method (6 ) , but it requires ultracentrifugation, uses large volumes of serum, and is a time-consuming and expensive technique. For that reason, most clinical laboratories estimate LDL-C concentrations in serum by the Friedewald formula (FF) (7 ) from concentrations of total cholesterol (TC), triglycerides (TGs), and HDL-cholesterol (HDL-C). Although the estimation method correlates highly with ␤-quantification, it has certain limitations: it is not valid in specimens with chylomicrons, with TGs Ͼ4000 mg/L, or in patients with dysbetalipoproteinemia (8 ) . Indeed, it has been recommended that the FF should be used with precaution in several pathologic states (diabetes, hepatopathy, nephropathy), even if TG concentrations are between 2000 and 4000 mg/L (9 ) .
The NCEP Working Group on Lipoprotein Measurements (10 ) has recommended that the LDL-C concentration be determined with a total analytical error not exceeding Ϯ 12% (Յ4% imprecision and Յ4% inaccuracy) to guarantee correct patient classification into the NCEP risk categories. It is difficult to obtain this analytical quality with FF because each component's analytical error is added.
To improve this situation, various methods have been developed based on selective chemical precipitation or immunoseparation of LDL (11, 12 ) and subsequent cholesterol quantification. However, results have not been very good: the methods are quite hard to perform and expensive, and TG interferences and substantial bias compared with the reference method have been reported (13 ) .
Since 1998, different homogeneous methods have been described that use different approaches that can be run in most clinical chemistry analyzers without the need for a separation step. These methods seem to have an important role in the future and should be analytically and clinically validated before being introduced into routine clinical laboratories.
The aim of the present study is to assess the analytical and clinical performance of two new direct methods marketed by Roche and Wako. The results obtained with these procedures were compared with the ultracentrifugation/phosphotungstic acid method (modified ␤-quantification method for LDL-C) in samples of adult patients with HPL from a lipid clinic.
Materials and Methods procedures
Roche homogeneous LDL-C assay. The LDL-C assay (cat. no. 1985604; Roche Diagnostics) was performed according to manufacturer's specifications on a Hitachi 911 analyzer. We used a lyophilized calibrator provided by the manufacturer. The assay contains two ready-to-use reagents. Reagent 1 is a solid reagent (pH 7.0) containing nonionic surfactant, dextran sulfate, ␣-cyclodextrin, and MgCl 2 . Its purpose is to reduce the enzymatic reaction for cholesterol in VLDL and chylomicrons. After a 5-min incubation, reagent 2 (cholesterol esterase, cholesterol oxidase, and aminoantipyrine) is added and forms a colored product with the selectively solubilized LDL-C.
Wako homogeneous LDL-C assay. The LDL-C assay (cat. no. 411-24017; Wako) contains two ready-to-use reagents. Reagent 1 is a detergent, which binds and protects LDL from enzyme reactions. The non-LDL cholesterol reacts with cholesterol esterase and cholesterol oxidase, producing hydrogen peroxide, which is consumed by a catalase. After 5 min, reagent 2 is added, the protecting agent is removed from LDL, and cholesterol esterase and cholesterol oxidase react only with the LDL-C. The hydrogen peroxide produced yields a color complex with a salt and peroxidase. The assay was carried out on a Hitachi 911 analyzer and calibrated using the lyophilized material provided by the manufacturer.
TC, TGs, and HDL-C. TC and TG concentrations were determined enzymatically with the CHOD-PAP (cat. no. 1489704; Roche Diagnostics) and lipase/GPO/PAP (cat. no. 1488902; Roche Diagnostics) methods, respectively, on a Hitachi 747 automatic analyzer. The total CV was 1.0 -1.5% for the cholesterol and 1.1-2.0% for TGs. The HDL-C was subsequently measured by precipitation with phosphotungstic acid and MgCl 2 (Roche Diagnostics). After incubation, the apoprotein B-containing lipoproteins were sedimented by centrifugation, and the cholesterol component was measured in the supernatant with a CHOD-PAP method on a Hitachi 911 analyzer. The total CV was 1.3-3.4%. Our laboratory meets the annual standardization for lipids through the Lipid Standardization Program of the CDC.
Modified ␤-quantification method. A NaCl solution (1.5-mL; d ϭ 1.006 kg/L) was added to a 1.5-mL serum sample and centrifuged at 541 000g for 2.5 h at 16°C in a TLA 100.3 rotor with 13 ϫ 56 mm polycarbonate tubes (Beckman Instruments), and 1.5 mL of the floating layer (containing TG-rich lipoproteins) was removed (14 ) . The VLDL-cholesterol (VLDL-C) was calculated as the difference between TC and that in the ultracentrifuged bottom fraction. The HDL-C in the infranate (the fraction containing the LDL and HDL) was determined as described above. The LDL-C concentration (UC-LDL) was then calculated by subtracting HDL-C from the total infranate cholesterol. The total CV for the period of study was Ͻ10%.
Friedewald calculation. LDL-C was estimated by the FF as follows: LDL-C ϭ TC Ϫ (TG/5) Ϫ HDL-C, in specimens with TGs Ͻ4000 mg/L.
analytical performance evaluation
Precision. Two human serum pools with medium and high LDL-C concentrations and one commercial control (Precinorm L; cat. no. 1240161; Roche Diagnostics) were used. Intraassay imprecision was calculated as the mean variance obtained for 20 replicate analyses during 1 day. To assess interassay imprecision, aliquots of control and pools stored at Ϫ40°C were analyzed over 20 consecutive days.
Total error. Total error (15 ) was calculated by adding the systematic error and the random error. Systematic error, including the constant and the proportional error, was calculated from the linear regression equation y ϭ bx ϩ a, where b is the slope of the regression equation and represents the proportional error, and a is the y-axis intercept and represents the constant error. Systematic error at a particular LDL-C concentration (x c ) was defined as the absolute value of y c Ϫ x c , where y c ϭ bx c ϩ a. The linear regression equation for calculation of systematic error was based only on specimens with TGs Ͻ2000 mg/L, according to CDC recommendations (15 ) . Random error was defined as the interassay imprecision multiplied by 1.96.
Linearity. We tested the range of linearity by adding various amounts of isotonic 9 g/L NaCl to the serum pool with high LDL-C. The analyses were done by triplicate on two different series.
Bilirubin, hemoglobin, and TG interference. The hemoglobin (up to 5.3 g/L) and bilirubin (up to 233 mg/L) interference was measured according to the method of Glick et al. (16 ) . Interference from TGs was determined by isolating TG-rich lipoproteins by ultracentrifugation at dϭ 1.006 kg/L, as described above. Various amounts of these lipoproteins were added to pooled serum with a medium LDL-C concentration to obtain TG concentrations of 575-11 505 mg/L. We defined interference as recovery of Ͼ5% of the initial measured value.
Stability study. Two serum pools (at low and high LDL-C concentrations) were prepared and stored in aliquots at Ϫ20 and Ϫ40°C. LDL-C concentrations were measured weekly with the two homogeneous assays over an 8-week period.
samples Blood samples were obtained from 291 outpatients and 22 control subjects, ages 19 -65 years, at the lipid clinic of Galdakao Hospital, Vizcaya, Spain. The outpatients attended hospital for routine checks of lipid-lowering medication (44%) or HPL diagnosis (56%). Blood was collected in tubes without anticoagulant from subjects after a 12-h fast. The samples were allowed to clot at room temperature, and serum was obtained by centrifugation at 2000g for 15 min. All direct and ultracentrifugation method analyses were performed within 2 days, and serum was stored at 4°C. Subjects with fasting TG concentrations Ͼ10 000 mg/L were excluded because of the manufacturer's recommendation. The study lasted 4 months. All procedures were in accordance with the Helsinki Declaration of 1975, as revised in 1996.
In addition, nine patients with familial type III hyperlipidemia were evaluated separately by the homogeneous methods. Type III hyperlipoproteinemia was diagnosed clinically and analytically based on mixed HPL with a VLDL-C/TG ratio Ͼ0.30 and apolipoprotein E2 genotype.
comparison between methods
LDL-C concentrations measured by the Roche (n ϭ 166) or Wako (n ϭ 145) methods and modified ␤-quantification were compared. For this purpose, samples were classified into four groups according to their TC and TG concentrations: (a) normolipidemia, defined as cholesterol Յ2400 mg/L and TGs Յ2000 mg/L; (b) type IIa HPL, defined as cholesterol Ͼ2400 mg/L and TGs Յ2000 mg/L; (c) type IIb HPL, defined as cholesterol Ͼ2400 mg/L and TGs Ͼ2000 mg/L; and (d) type IV HPL, defined as cholesterol Յ2400 mg/L and TGs Ͼ2000 mg/L. Subjects from the control group were subsequently included in the normolipidemic group, except for two, who were included in type IIa HPL.
diagnostic performance
According to NCEP Adult Treatment Panel guidelines (5 ) , the management of hyperlipidemic patients, using either dietary or drug therapy, is based on LDL-C cutoff points (Ͻ1000, Ͻ1300, and Ͻ1600 mg/L). Misclassification occurs if a true LDL-C set point is within the range for desirable risk and the reported LDL-C is in the range for high risk (or vice versa). We assessed the ability of two homogeneous assays to correctly classify subjects at the above medical decision cutoff points.
The positive predictive value (PPV) of an LDL-C assay at the x cutpoint was defined as [true positive/(true positive ϩ false positive)] ϫ 100, where true positive means that the LDL-C results obtained with both the reference and the test method are Ͼx mg/L, and false positive means that the test method LDL-C result is Ͼx mg/L when the reference method LDL-C result is Ͻx mg/L. The negative predictive value (NPV) of an LDL-C assay at the x cutpoint was defined as [true negative/(true negative ϩ false negative)] ϫ 100, where true negative means that the LDL-C results obtained with both the reference method and the test method are Ͻx mg/L, and false negative means that the test method LDL-C result is Ͻx mg/L when the reference method LDL-C result is Նx mg/L.
We also evaluated the possible utility of the homogeneous assays to diagnose type III HPL by estimating the VLDL-C concentration and VLDL-C/TG ratio. The calculation was made according to the following equation: VLDL-C ϭ TC Ϫ LDL-C Ϫ HDL-C, where LDL-C is the LDL-C determined by each of the direct methods.
statistical analysis
Descriptive statistics (means, SDs, and CVs) were calculated with Microsoft Excel, Ver. 5.0R (Microsoft) and the software Astute Statistics Add-in program for Microsoft Excel (1993-1995 DDU software). The nonparametric regression procedure developed by Passing and Bablok (17 ) was used for the method comparison. Plotting the method differences against the method means as recommended by the Bland and Altman procedure (18, 19 ) assessed the degree of agreement between methods. The mean of the differences and 95% limits of agreement were also included in the plots. The Wilcoxon test was used to compare data that did not follow a gaussian distribution. Biases were calculated as test procedure result Ϫ reference procedure result. Differences were considered significant at P Ͻ0.05.
Results precision
The precision profile of the homogeneous assays performed with the Precinorm L and the human serum pools with medium and high concentrations of LDL-C are shown in Table 1 . The total CVs for all three concentrations were 1.3-2.0% for the Roche method and 1.2% for the Wako method. According to the NCEP performance goals, LDL-C must be determined with an imprecision Յ4%. The two homogeneous assays have met this performance criterion.
total error
The linear regression equations based on specimens with TGs Ͻ2000 mg/L for systematic error calculations were y ϭ 1.011x Ϫ 72 mg/L for the Roche method and y ϭ 0.923x ϩ 103.1 mg/L for the Wako method. The total error calculated at different concentrations used in the precision study was 5.53-10.69% for the Roche method and 2.60 -5.62% for the Wako method ( Table 1 ). The total analytical error of the two homogeneous assays was Ͻ12%, as recommended by the NCEP (10 ).
linearity
The Roche method was linear up to at least 4100 mg/L. The regression equation for the measured LDL-C vs the expected LDL-C values from a dilution series was: y ϭ 1.013x Ϫ 27.5 mg/L. The Wako method was linear up to 3000 mg/L; the regression equation was: y ϭ 0.967x ϩ 1.64 mg/L. Regression analysis showed that slopes and intercept did not differ significantly from 1 and 0, respectively.
interferences Bilirubin concentrations up to 234 mg/L did not interfere with the homogeneous LDL-C assays (Fig. 1A) . Hemoglobin concentrations Ͼ3.7 g/L produced a slight increase in Roche LDL-C measurements (Fig. 1B) . There was no interference from TGs up to 7000 mg/L in both methods (Fig. 1C ). TG interference was 5-10% for both methods for TG concentrations of 7000 -10 000 mg/L; TG interference showed a tendency to decrease the Roche LDL-C result and to increase the Wako result. We have also observed very different biases depending on the sample used to isolate the TG-rich lipoproteins.
storage
The means of LDL-C concentrations determined by two homogeneous assays of two serum pools at baseline and after storage periods of 1-8 weeks at Ϫ20 and Ϫ40°C are presented in Fig. 2 . The initial concentration was considered 100%, and the plots showed no significant change in LDL-C concentrations during the 2 months.
comparison between direct methods and modified ␤-quantification
The lipid and lipoprotein concentrations of the study population are summarized in Table 2 . There were no differences between patients taking lipid-lowering medications and those not taking medication and between of populations of the Roche and Wako methods.
The comparison-of-methods plot [UC-LDL (x) vs test method (y)] in all patients showed a regression equation of y ϭ 0.915x ϩ 104.8 mg/L (r ϭ 0.966; n ϭ 145) for the Wako method and y ϭ 1.052x Ϫ 168.8 mg/L (r ϭ 0.929; n ϭ 176) for the Roche method ( Fig. 3 ). The correlation coefficients comparing the homogeneous assays with ␤-quantification were highly significant. The Wako method did not under-or overestimate LDL-C values, as shown by the mean difference of Ϫ14.6 Ϯ 97 mg/L (Ϫ0.4% Ϯ 6.7%). With the Roche method, bias was Ϫ95.0 mg/L (Ϫ6.6% Ϯ 9.5%). This gave a negative systematic error.
To more clearly illustrate the performance of the homogeneous assays, we compared the results in HPL groups separately (Table 3 ). In the normolipidemic and type IIa HPL groups (patients with TGs Ͻ2000 mg/L), the correlation coefficients between the direct methods and ␤-quantification were highly significant, and the regression lines were near identity. Agreement with ␤-quantification using the Altman-Bland technique (Fig. 4A) was good, but the Roche method showed a negative bias (Ϫ4.5% Ϯ 5.7%) that did not depend on LDL-C concentration.
The correlation and degree of agreement between the direct methods and ␤-quantification were worse in other HPL groups: the correlation coefficients were lower and values showed a considerable degree of dispersion above or below the mean ( Table 3 and Fig. 4, B and C). The Roche method showed negative biases in type IIb (Ϫ7.9% Ϯ 9.6%) and type IV (Ϫ14.3% Ϯ 18.3%) HPL. The Wako method did not show a significant bias: Ϫ2.70% Ϯ 11.7% in type IIb HPL and Ϫ2.5% Ϯ 8.8% in type IV HPL. In type IIb HPL patients, 25% had values outside the limits of agreement for the Roche method and 16% had values outside the limits of agreement for the Wako method, whereas in the type IV HPL group, 19% and 6% of patients had values outside the limits of agreement for the Roche and the Wako methods, respectively.
We studied bias between homogeneous assays and ␤-quantification associated with TC, TG, and HDL-C concentrations. There was no increase in bias when TC, TG, or HDL-C concentrations increased: Roche method, r ϭ 0.032, 0.078, and 0.006, respectively; Wako method, r ϭ 0.018, 0.013, and 0.001, respectively. We found a positive correlation (Roche, r ϭ 0.24; Wako, r ϭ 0.30) between bias and the VLDL-C/TG ratio (Fig. 5 ). This suggests that the VLDL composition may be a source of variability in the homogeneous assays evaluated.
appropriate classification
We studied the appropriate classification by homogeneous assays and FF into the NCEP categories with LDL-C values coinciding within Ϯ 10% of UC-LDL. As seen in Table 4 , LDL-C concentrations determined by the two homogeneous assays correctly classified Ͼ98% of patients with TGs Ͻ2000 mg/L (normolipidemia and type IIa HPL), and the FF correctly classified 95%. The Roche method did not correctly classify 25% and 16% of the patients with type IIb HPL and type IV, respectively, whereas for the same groups, the Wako method did not correctly classify 21% and 11% of the patients. Both direct methods correctly classified 91% of the patients with TGs between 3000 and 4000 mg/L, whereas the FF correctly classified only 76%. When TG concentrations were 4000 -10 000 mg/L, the Roche method correctly classified 74.8% of patients and the Wako correctly classified 86%. We calculated the PPV of each LDL-C method at the NCEP cutpoints of 1000, 1300, 1600, and 1900 mg/L ( Table 5 ). The Roche method showed a PPV of 90.3-99.0% and a NPV of 74.4 -96.7%, and the Wako method showed a PPV of 92.4 -100.0% and a NPV of 92.5-100.0% compared with the reference method. In contrast, the FF showed a PPV of 83.3-98.4% and a NPV of 44.4 -91.5%.
comparison in type iii hpl
Because the FF is invalid in type III HPL, it is important to have an assay that can reliably determine LDL-C concentrations in these patients. Nine patients with diagnosed type III hyperlipoproteinemia were analyzed by two homogeneous assays. Their lipid and lipoprotein values are shown in Table 6 . As seen, the mean LDL-C determined by both direct methods was significantly higher than that of UC-LDL, with a mean positive bias of 30%.
We also calculated VLDL-C concentrations and the VLDL-C/TG ratio by the equation described above. In only one patient (12%) would it have been possible to suspect the presence of ␤-VLDL by a ratio between 0.25 and 0.30. In no patients with type III HPL was the calculated ratio Ͼ0.30, which implies that these homogeneous assays are not useful for this type of patient.
Discussion
LDL-C plays a causal role in the development of atherosclerosis. The recommendations of the NCEP define hypercholesterolemia and use LDL-C as the primary criterion for the diagnosis and treatment of patients with HPL. Classically, the measurement of LDL-C required the separation of LDL particles in serum from other lipoproteins and the subsequent measurement of cholesterol in the LDL fraction. For that reason, routine clinical chemistry laboratories indirectly calculated LDL-C concentrations from TC, TG, and HDL-C concentrations using the FF, which assumed that the relationship between cholesterol and TGs in VLDL was constant. Warnick et al. (20 ) stated that when the TG concentration was Ͻ2000 mg/L, Ͼ90% of the calculated LDL-C values determined by the formula were acceptable, within Ϯ 10% of the values after ultracentrifugation. However, clinical conditions can induce changes in the concentration and/or composition of lipoproteins that seriously reduce the applicability of the FF. Important errors have been described in mixed dyslipemias and secondary HPLs attributable to hepatopathies, nephropathies, or diabetes. In these cases, it is recommended to refer the patient or the sample to a specialized laboratory for lipoprotein measurement by ultracentrifugation separation.
The NCEP Working Group on Lipoprotein Measurement (10 ) has been developing recommendations for LDL-C measurement and has recommended further research to develop new assays capable of directly quantifying LDL-C without previous separations or calculations. New assays to directly quantify LDL-C in serum and plasma must be comparable to the accepted reference procedure to maintain linkage with the epidemiological database. The LDL-C isolated by ultracentrifugation contains LDL, intermediate-density lipoproteins, and lipoprotein(a). Because intermediate-density lipoproteins and lipoprotein(a) are atherogenic, the LDL-C measure- ment actually represents the amount of cholesterol being transported in atherogenic particles. The new direct methods must include these atherogenic lipoproteins. Thus, direct routine methods should be validated against the reference method, and standards and control materials should be traceable to the reference method for LDL-C.
Direct methods for LDL-C are new in clinical laboratories, and they are easily adapted to automatic analyzers to quantify LDL-C concentration without the need for sample pretreatment. Here we present the results of two new homogeneous assays that use different strategies: In the Roche method (21 ) , the LDL-C is determined directly using selective micellar solubilization of LDL-C by a nonionic detergent and the interaction of sugar compound and lipoproteins. In the second step, the cholesterol in the solubilized LDL fraction is determined enzymatically. The Wako homogeneous assay (22 ) uses the combination of a polyanion and amphoteric surfactant as the protecting reagent for LDL. In the second step, both are removed from LDL by a nonionic surfactant and the LDL-C is determined enzymatically. Although the mechanisms involved in the selectivity of the different surfactants and reagents are not exactly known, they could be related to the differences in net charge, hydrated density, or size of various lipoprotein fractions (23 ) .
The NCEP has clearly laid down the analytical goal for the acceptability of any new assay measuring LDL-C (10 ):
The imprecision of LDL-C determinations should not exceed 4%, and the total error should be Ͻ12%. In our experience, the precision of both direct assays is excellent and similar to that of other published reports (24, 25 ) . The total error is higher in the Roche method (5.5-10.3%) than in the Wako method (3.0 -5.3%) because of constant negative error. Even with this negative bias, the method meets the total error goal because of the very low imprecision. If we adjust the calibrator to 97% of its preliminary target value, the total error will be 2.5-7.5%. The systematic difference could be easily corrected with appropriated reference materials. The value assignment for calibrators is critical for accuracy from lot to lot of homogeneous assays and makes obvious the problems derived from the lack of a true reference method for LDL-C measurement.
The Wako method was linear up to 3000 mg/L, whereas the Roche method was linear to 4000 mg/L. Therefore, the recovery of high LDL-C concentrations with the Wako method may be lower, and samples should be diluted beforehand. The stability of samples was good for at least 2 months at Ϫ20 and Ϫ40°C, which means a practical advantage in clinical laboratories, although longer studies would be necessary if these methods are considered for longitudinal trials. Neither bilirubin nor hemoglobin interference was observed at the concentrations studied with the Wako method. In the Roche method, a positive interference was observed when the hemoglobin concentration was Ͼ4 g/L. TG concentrations up to 7000 mg/L did not interfere significantly (Ͻ5%) in either method. Although deviation for higher concentrations (7000 -10 000 mg/L) did not exceed 10%, the Roche assay tended to experience a negative bias and the Wako assay a positive bias. The TG-related bias may be dependent on the nature and/or composition of the TG-rich lipoproteins used in the interference studies. Furthermore, the method bias data plotted as a function of TG concentration did not show a significant correlation. At serum triglyceride concentrations Ͼ10 000 mg/L, both homogeneous LDL-C methods suffered from serious interferences, leading to underestimation of LDL-C concentrations.
The method comparison studies confirmed the negative bias of the Roche method in all patient groups studied. However, there was an acceptable agreement among results with wider limits for type IIb and type IV HPL. With the Wako method, no bias was noticed in any group. Certain dependence with LDL-C values in type IIa HPL was observed, which reflects the lack of linearity for values Ͼ3000 mg/L. In type IIb and IV HPL patients, the agreement limits were also more scattered than in patients with TGs Ͻ2000 mg/L.
The differences between each direct method and ␤-quantification were not related to HDL-C, TC, or TG concentrations. We found in both methods that there is a significant correlation with the VLDL-C/TG ratio. This implies dependence between VLDL composition and the deviations of the direct methods with respect to ␤-quantification. An increase in serum TGs is indicative of the presence of a variety of TG-rich lipoproteins. Particles found in hypertriglyceridemic samples (type IIb and type IV HPL) often are a heterogeneous mixture of VLDL, chylomicron remnants, and VLDL remnants. The percentages of cholesterol and TGs are very different across this range of particles, and they could affect the differences found in these patients. When VLDL is rich in TG (lower ratio), direct methods tend to underestimate LDL-C. This, together with the wider deviations found in samples with high TG concentrations (Ͼ10 000 mg/L), implied that an incomplete measurement was performed in this situation or that perhaps, all of the LDL of "wide-density" was not measured. Okada et al. (26 ) have reported that direct LDL values were influenced by the size of the LDL particle. When the VLDL was rich in cholesterol (high ratio), bias was positive. The most outstanding case was observed in patients with type III HPL, for whom the bias was 30%. In these patients, a serum VLDL-C/TG ratio Ͼ0.30 (measured in mg/L) reflects the presence of ␤-VLDL. This ␤-VLDL contains atypical lipoproteins with d Ͻ1.006 kg/L and mobility ␤ in agarose gel. The simplest expla- nation would be that direct methods recognize the ␤-VLDL and other cholesterol-rich VLDLs as LDL; consequently, part of their cholesterol is quantified together with that of the LDL. Other authors (27 ) have reported that ␤-VLDL in patients with type III HPL positively interferes with HDL-C direct methods based on polyethylene glycol-modified enzymes. LDL homogeneous assays have not been successful in detecting type III HPL. The overestimation of LDL-C can cause a type III patient to be misdiagnosed as having type IIb HPL. The presence of abnormal lipoproteins in other patients with diabetes, renal insufficiency, and hepatopathies could lead to similar problems, and further studies are necessary.
According to the NCEP Adult Treatment Panel II, LDL-C Ͻ1300 mg/L is considered desirable and LDL Ͼ1600 mg/L is considered high. Patients with coronary heart disease are recommended to maintain their LDL-C at Ͻ1000 mg/L. An incorrect classification could generate unnecessary drug administration or inappropriate treatment. Ninety-eight percent of patients were correctly classified when TG concentrations were Ͻ2000 mg/L by the two homogeneous assays evaluated. Similar data were obtained by the FF. The Roche method could not correctly classify 25% of patients with mixed HPL (type IIb), and the Wako method could not correctly classify 15%. In the hypertriglyceridemic group (type IV), 16% (Roche method) and 12% (Wako method) of patients would be incorrectly classified. However, we must be aware that incorrect classification by the Roche method could be lower if the bias is corrected. From a clinical point of view, these results can be considered an important improvement over the FF, which is used when TG concentrations are Ͻ4000 mg/L and which classifies up to 25% of patients incorrectly when TG concentrations are 3000 -4000 mg/L. This percentage could be even greater because we used the HDL-C concentration of fraction (d Ͼ1.006 kg/L) isolated by ultracentrifugation. Therefore, the type IIb HPL group of patients has to be observed cautiously because of the possible consequences derived from treatment, whereas in type IV HPL patients, errors occur at lower LDL-C concentrations. This study was deliberately designed with samples from patients attending a lipid clinic who had severe disorders in lipoprotein composition and concentration to evaluate the methods under unsuitable conditions. We also want to remark on the need to determine TC, TG, and HDL-C concentrations to identify dyslipemic patients. It is not advisable to measure LDL-C alone. The correct way to evaluate coronary risk and the effect of hypolipemiant drugs intervention would be to perform a complete lipid profile. When TG concentrations are Ͻ2000 mg/L, we recommend the use of the FF to calculate LDL-C concentrations because of its low cost. The direct LDL-C methods can be useful for mixed HPL and hypertriglyceridemia if ultracentrifugation is not available, although they are not valid for the dysbetalipoproteinemia.
In summary, the homogeneous assays evaluated meet the currently established analytical performance goals and show an important improvement for practicability compared with ␤-quantification or with other described direct methods, which are time-consuming and cumbersome. The homogeneous methods show a good correlation with ␤-quantification, which implies that they are capable of measuring the LDL, intermediate-density lipoproteins, and lipoprotein(a). The constant negative bias seen with the Roche method is attributable to the wrong assignment of the calibrator value, which indicates the importance of this factor and needs be solved by manufacturers. The diagnostic efficiency in patients with mixed HPL and hypertriglyceridemia (types IIb and IV) is good, although 25% and 15% (Roche and Wako methods, respectively) of patients could be classified incorrectly. It is advisable to be cautious with these types of patients. None of these methods could be performed on dysbetalipoproteinemic (type III HPL) patients, but they provide to clinical laboratories the capacity to analyze a high number of samples using an automatic analyzer. They can be considered a good alternative for clinical laboratories when the reference method for the control of hypolipemiant treatment in patients with disorders of lipid metabolism is not available.
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